Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination drug composed of dipyrone (also known as metamizole), isometheptene, and caffeine, commonly used for the acute treatment of mild-to-moderate primary headache disorders, including tension-type headache and migraine. **Dipyrone** is a potent non-opioid analgesic and antipyretic that works by inhibiting prostaglandin synthesis, leading to reduced pain and fever. **Isometheptene** is a sympathomimetic amine that acts as a cranial vasoconstrictor, attributed to its activation of alpha-adrenergic receptors, thereby reducing dilation of cerebral vessels and potentially alleviating headache. **Caffeine** enhances the vasoconstrictive effect and also provides mild analgesic adjuvant properties via adenosine receptor antagonism. The combination is designed to provide synergistic pain relief through these complementary mechanisms. Multiple randomized studies have shown efficacy and excellent tolerability for acute headache episodes[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dipyrone + isometheptene + caffeine.